Larimar Therapeutics, Inc. Common Stock(LRMR)
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
Snapshot
$3.51
- 52-Week Range
- $2.22 – $6.42
- YTD
- +1.15%
- IV Rank (30D)
- 35.21
- Straddle Price
- $4.60
- P/C Vol Ratio
- 0.01
- Market Cap
- $0.4B
Fair Value
+20.0% vs price
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 0.5% and dividend payments are stable.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.53% |
| Beta vs SPY | 1.00 |
| Cost of Equity (CAPM) | 10.03% (VRP-adj) |
| WACC | 10.01% |
| Volatility Risk Premium | +221.0pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.1B |
| Return on Equity (TTM) | -105.0% |
| Book / Price | 57.5% — banking bias active (P/B is primary) |
| Debt / Equity | 0.00 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $4.08 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $3.43 |
| Bollinger Width / SMA20 | 603.3% (drives anchor stability) |
| Net Debt | $-0.2B |
| Market Cap | $0B |
Peers used for multiples: BIIB, REGN, UTHR
(filtered from 8 ETF-co-members; sector bias active)
Blended Fair Value
$4.16
Current Price
$3.47
Deviation
+20.0%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 17.9× · 3 peers |
| Peer EV/EBITDA | n/a | 0% | median 14.3× · 3 peers |
| Peer P/B | $4.16 | 100% | median 2.0× · 3 peers |
| Peer P/S | n/a | 0% | median 4.2× · 3 peers |
| Market Anchor (SMA50) | $4.08 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
As of 2026-06-12 · updated 2026-06-12 20:59:55.687000
Info
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834)
- Exchange
- XNAS
- Market Cap
- $0.4B
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target addit…
Price History
Seasonality
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | +1.18% | 6 |
| Feb | +12.45% | 6 |
| Mar | -20.68% | 6 |
| Apr | -1.47% | 6 |
| May | -10.09% | 6 |
| Jun | -3.03% | 6 |
| Jul | +11.21% | 5 |
| Aug | +19.04% | 5 |
| Sep | -3.08% | 5 |
| Oct | +10.13% | 5 |
| Nov | -8.34% | 5 |
| Dec | +9.71% | 5 |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $3.41
SMA 50: $4.06
SMA 200: $3.99
Current: $3.47
EMA 12: $3.43
EMA 26: $3.60
MACD: -0.1631 | Signal: 0.0542
BEARISH
ADX (14): 23.53
WEAK TREND
+DI: 22.28
−DI: 18.52
Momentum Oscillators
RSI (14): 45.78
NEUTRAL
Stoch %K: 71.38
Stoch %D: 65.08
Williams %R: -37.41
Volume & Volatility
BB Upper: $3.70
BB Lower: $3.12
NEUTRAL
OBV: 97,968,554
Vol SMA 20: 1,944,937
Vol ROC: 20.82%
ATR: $0.24
True Range: $0.30
HV 20: 79.7%
HV 30: 73.6%
HV 60: 63.2%
Data Summary
Data Points: 500
Last Updated: 2026-06-13T13:41:39.205000
Date Range: 2024-06-14T00:00:00 – 2026-06-12T00:00:00
AI Analysis
Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
News
Earnings History
8 of 8 under expected move
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2024-08-07 | After-Close | 14.69% | 4.06% | 0.28x | Within |
| 2024-10-30 | After-Close | 21.05% | 3.86% | 0.18x | Within |
| 2025-03-24 | Pre-Market | 207.68% | 9.06% | 0.04x | Within |
| 2025-07-29 | After-Close | 239.69% | 40.28% | 0.17x | Within |
| 2025-11-05 | Pre-Market | 64.47% | 15.26% | 0.24x | Within |
| 2026-01-12 | After-Close | 89.93% | 3.63% | 0.04x | Within |
| 2026-03-19 | Pre-Market | 19.16% | 5.34% | 0.28x | Within |
| 2026-05-14 | After-Close | 74.94% | 8.14% | 0.11x | Within |
Options Activity
- IV Rank (30D)
- 35.21
- IV Rank (7D)
- 61.81
- Avg IV
- 281.7%
- Straddle (30D)
- $4.60
- Straddle (7D)
- $1.68
- P/C Volume
- 0.01
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
14 DTE / 10d
—
—
pts
ATM — / Wing —
30 DTE / 10d
—
—
pts
ATM — / Wing —
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
- Beta (1Y vs SPY)
- 2.09
- Correlation (SPY)
- 22.9%
- R²
- 0.05
- Ann. Volatility
- 112.6%
- SPY Volatility
- 12.3%
High volatility - stock moves more than market
Beta & Alpha Over Time
Institutional Ownership (13F)
Latest filings — 2026-03-31
? 13F Guide
Diluted shares outstanding: 76,278,851 (as of 2026-03-31)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
8 filers$3.57M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | SIMPLEX TRADING, LLC Custodian | $841.05K | 23.54% | 2026-03-31 |
| 2 | SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian | $740.70K | 20.73% | 2026-03-31 |
| 3 | Caption Management, LLC | $738.90K | 20.68% | 2026-03-31 |
| 4 | GROUP ONE TRADING LLC Custodian | $556.65K | 15.58% | 2026-03-31 |
| 5 | GOLDMAN SACHS GROUP INC Custodian | $405.00K | 11.34% | 2026-03-31 |
| 6 | CITADEL ADVISORS LLC Custodian | $144.90K | 4.06% | 2026-03-31 |
| 7 | JANE STREET GROUP, LLC Custodian | $117.00K | 3.28% | 2026-03-31 |
| 8 | HAP TRADING, LLC | $28.01K | 0.78% | 2025-09-30 |
5 filers$1.67M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian | $823.50K | 49.26% | 2026-03-31 |
| 2 | JANE STREET GROUP, LLC Custodian | $347.40K | 20.78% | 2026-03-31 |
| 3 | CITADEL ADVISORS LLC Custodian | $219.60K | 13.14% | 2026-03-31 |
| 4 | SIMPLEX TRADING, LLC Custodian | $207.90K | 12.44% | 2026-03-31 |
| 5 | GROUP ONE TRADING LLC Custodian | $73.35K | 4.39% | 2026-03-31 |
Insider Activity
Latest: 2026-05-20
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-05-20 | JEFFREY W SHERMAN | Director | Grant (A) | +55,150 opt | — | EDGAR | |
| 2026-05-20 | Thomas Edward Hamilton | Director | Grant (A) | +55,150 opt | — | EDGAR | |
| 2026-05-20 | JONATHAN S LEFF | Director | Grant (A) | +55,150 opt | — | EDGAR | |
| 2026-05-20 | Joseph Truitt | Director | Grant (A) | +55,150 opt | — | EDGAR | |
| 2026-05-20 | DEERFIELD MANAGEMENT COMPANY, L.P. | Director | Grant (A) | +110,300 opt | — | EDGAR | |
| 2026-05-20 | FRANK E THOMAS | Director | Grant (A) | +55,150 opt | — | EDGAR | |
| 2026-03-02 | FRANK E THOMAS | Director | Buy (P) | +5,000 | $5.00 | $25.0K | EDGAR |
| 2026-03-02 | JEFFREY W SHERMAN | Director | Buy (P) | +5,000 | $5.00 | $25.0K | EDGAR |
| 2026-03-02 | Thomas Edward Hamilton | Director | Buy (P) | +100,000 | $5.00 | $500.0K | EDGAR |
| 2026-03-02 | Deerfield Mgmt III, L.P. | Director | Buy (P) | +50,000,000 | $5.00 | $250.00M | EDGAR |
| 2026-01-27 | Gopi Shankar | Chief Development Officer | Award (A) | +25,637 | — | EDGAR | |
| 2026-01-27 | CAROLE BEN-MAIMON | President and CEO | Award (A) | +100,100 | — | EDGAR | |
| 2026-01-27 | Russell Clayton | Chief Medical Officer | Award (A) | +25,637 | — | EDGAR | |
| 2026-01-27 | Michael Celano | Chief Financial Officer | Award (A) | +37,604 | — | EDGAR | |
| 2025-08-04 | DEERFIELD PARTNERS, L.P. | Director | Buy (P) | +93,750,000 | $3.20 | $300.00M | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
Insider Holdings
14 insiders · @ $3.47
Officers, directors, and 10%+ owners ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | DEERFIELD PARTNERS, L.P. | Director | 9,538,945 | $33.10M | $300.00M | 1 | 2025-08-04 |
| 2 | Deerfield Mgmt III, L.P. | Director | 6,207,982 | $21.54M | $250.00M | 1 | 2026-03-02 |
| 3 | Deerfield Mgmt IV, L.P. | Director | 4,721,197 | $16.38M | $375.00M | 1 | 2024-02-16 |
| 4 | Deerfield Healthcare Innovations Fund, L.P. | Director | 4,721,183 | $16.38M | $280.00M | 1 | 2022-09-20 |
| 5 | James E Flynn | Director | 1,943,423 | $6.74M | $48.00M | 1 | 2021-07-02 |
| 6 | Thomas Edward Hamilton | Director | 824,231 | $2.86M | $2.50M | 11 | 2026-05-20 |
| 7 | CAROLE BEN-MAIMON | President and CEO | 399,432 | $1.39M | $118.5K | 11 | 2026-01-27 |
| 8 | Michael Celano | Chief Financial Officer | 215,785 | $748.8K | $118.6K | 11 | 2026-01-27 |
| 9 | Gopi Shankar | Chief Development Officer | 76,443 | $265.3K | $18.7K | 5 | 2026-01-27 |
| 10 | Russell Clayton | Chief Medical Officer | 71,443 | $247.9K | $0 | 4 | 2026-01-27 |
| 11 | FRANK E THOMAS | Director | 7,000 | $24.3K | $47.0K | 9 | 2026-05-20 |
| 12 | JEFFREY W SHERMAN | Director | 5,000 | $17.4K | $25.0K | 5 | 2026-05-20 |
| 13 | Joseph Truitt | Director | 2,750 | $9.5K | $10.3K | 8 | 2026-05-20 |
| 14 | CHONDRIAL THERAPEUTICS HOLDINGS, LLC | 10%+ Owner | 8 | $28 | $0 | 1 | 2020-06-30 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
ETF Holders
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
| P/B Ratio | 2.4 |
| EV/EBITDA | -1.1 |
| TTM Net Income | $-0.2B |
| TTM EPS | $-2.1 |
| ROE | -105.0% |